Gut microbiome modulation with probiotics and prebiotic fibre significantly reduced systolic blood pressure compared to placebo (-8 mmHg vs -3 mmHg, P=0.001) in pre-hypertensive patients.
RCT (n=300)
Double-blind
Randomly allocated
No
Does gut microbiome modulation with probiotics and prebiotic fibre reduce blood pressure in adult patients with pre-hypertension?
Gut microbiome modulation with probiotics and prebiotic fibre significantly reduced systolic blood pressure in pre-hypertensive patients, suggesting a potential novel lifestyle intervention for blood pressure management.
Tasa de eventos absoluta: -8% vs -3%
valor p: p=0.001
Objective: Recently, evidence has emerged which links gut microbiome with blood pressure (BP) regulation. Short chain fatty acids (SCFA) produced by microbiomes regulate the BP. This study was conducted with an aim to evaluate the effectiveness of gut microbiome modulation in lowering BP in pre-hypertensive patients. Design and method: This was a randomised, double-blind, placebo-controlled trial conducted at a tertiary care hospital for a duration of one year. Adult patients with pre-hypertension, defined as systolic BP of 130-139 mmHg and diastolic BP of 80-89 mmHg. The patients were randomly allocated to either intervention group or control group. Intervention group received a probiotic capsule which contained strains of Lactobacillus and Bifidobacterium and 10 g/day prebiotic fibre for six months. A similar looking placebo was administered to control group. Follow up was done at 3 and 6 months. The primary outcome was defined as change in office BP. Secondary outcomes were changes in ambulatory BP, composition of gut microbiome, levels of SCFA and adverse events. Relevant statistical analysis was conducted and P<0.05 was considered significant. Results: Total 300 patients were enrolled in the study. There was a significant reduction in the systolic BP in the intervention group as compared to control group (- 8 mmHg vs – 3 mmHg, P = 0.001). There was a significant improvement in ambulatory BP (P = 0.01). There was a 23.4% increase in the microbial diversity with an increase in SCFA-producing bacteria. Mild gastrointestinal discomfort was seen in 7.4% patients. No serious adverse event were observed. Conclusions: Modulating the gut microbiota may lower the BP and also improves microbial diversity in gut. Further studies must be conducted in larger sample size studies to identify appropriate doses of gut microbiota and mechanisms elucidating the lowering of BP.
Aashal Bhavesh Shah (Fri,) conducted a rct in Pre-hypertension (n=300). Probiotic capsule (Lactobacillus and Bifidobacterium) and prebiotic fibre vs. Placebo was evaluated on Change in office systolic blood pressure (p=0.001). Gut microbiome modulation with probiotics and prebiotic fibre significantly reduced systolic blood pressure compared to placebo (-8 mmHg vs -3 mmHg, P=0.001) in pre-hypertensive patients.